Targeting the BBB to treat CNS inflammation
靶向 BBB 治疗中枢神经系统炎症
基本信息
- 批准号:9275040
- 负责人:
- 金额:$ 28.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-25 至
- 项目状态:未结题
- 来源:
- 关键词:Abnormal CellAddressAffectAnimalsAutoimmune Diseases of the Nervous SystemAutopsyBiological MarkersBiological PreservationBiopsy SpecimenBloodBlood - brain barrier anatomyBlood VesselsBrainCNS autoimmunityCXCL11 geneCXCL12 geneCXCR4 ReceptorsCell PolarityCellsCellularityClinicalCuesDepositionDiffusionDiseaseDrug TargetingDrug usageEdemaEncephalitisEndothelial CellsEndotheliumEnhancing LesionExhibitsExperimental Animal ModelExperimental Autoimmune EncephalomyelitisExperimental DesignsGadoliniumHemorrhageHumanImageImmuneImmune systemIn SituIn VitroInfiltrationInflammationInflammatoryInvestigationLeadLesionLeukocyte TraffickingLeukocytesLocationLymphocyteMagnetic Resonance ImagingMediatingModalityMolecularMovementMultiple SclerosisMultiple Sclerosis LesionsMusMyelinNeuraxisOutcomePathogenesisPermeabilityPharmacologyProcessPublishingReceptor SignalingRelapseRoleSignal TransductionSiteSurfaceT-LymphocyteTestingTissuesTranslationsTransport VesiclesVascular PermeabilitiesVesicle Transport Pathwayautoreactivityaxon injurycell motilitychemokinecytokineexperimental studygenetic approachhuman tissueimaging approachimaging modalityin vivointravital imagingintravital microscopymembrane polaritymigrationmonocytemouse modelmultiple sclerosis patientmultiple sclerosis treatmentneuroimagingneuroinflammationnovelreceptorspectrographsphingosine 1-phosphatetraffickingtranscytosistwo-photon
项目摘要
Project 2 will determine how targeting molecules that regulate permeability and polarity at
central nervous system (CNS) endothelial barriers impacts neuroinflammation, as assessed via
novel neuroimaging modalities with murine models of multiple sclerosis (MS). We have shown
that endothelium in MS lesions exhibits altered polarity, displaying the abluminal chemokine
CXCL12 aberrantly along luminal surfaces. Abluminal CXCL12 normally serves to limit
leukocyte entry whereas luminal expression of CXCL12 is associated with increased activation
of its signaling receptor CXCR4 on infiltrating leukocytes. We showed that the scavenging
CXCL12 receptor, CXCR7 (also expressed by CNS endothelium), is a critical regulator of
leukocyte entry via internalization of CXCL12 from abluminal surfaces. In preliminary studies,
we have also found that sphingosine 1-phosphate (S1P) signaling via S1P2 disturbs abluminal
expression of CXCL12, which then disrupts immune privilege. Thus, mice with targeted deletion
of S1P2 or administered a specific antagonist, JTE-013, show reduced migration of leukocytes
into the CNS parenchyma during EAE. We hypothesize that alterations in membrane polarity of
CXCL12 at CNS endothelial barriers promote leukocyte capture and migration into the CNS,
contributing to the establishment of disease cycles in relapsing-remitting forms of CNS
autoimmunity. We have identified several molecules that regulate this process, leading to
reversal of apicobasal expression of the localizing cue, CXCL12. In this proposal, we will
examine the roles of CXCR7 and S1P2 in lymphocyte trafficking and inflammation in CNS
autoimmune disease using novel imaging modalities including two-photon intravital
microscopy and longitudinally using Diffusion Basis Spectrum Imaging (DBSI), which
distinguishes and quantitates cellularity and edema in live mice (see Project 1) and
examination of autopsied human MS patient and control CNS tissues.
We expect DBSI to be more sensitive than Gd enhancement to inflammation, including in the
setting of less profound blood-brain barrier alterations. To determine the relationships between
endothelial and immune cell (Th1 versus Th17) interactions and loss of BBB integrity, we will
directly compare results utilizing intravital imaging to DBSI and Gd enhancement in the same
animals. To address mechanisms by which endothelial cell polarity and localizing cues are
induced by interactions with inflammatory cells, we will utilize in vitro and in situ approaches with
human tissues. Thus, Aim 1 will determine whether CXCR7-mediated internalization of CXCL12
requires infiltration with Th1 versus Th17 cells during EAE. Aim 2 will determine whether S1P2-
mediated reversal of endothelial cell polarity leads to increased T cell capture and entry during
EAE, and Aim 3 will examine the relationship between CXCR7 and S1PR2 activation and T cell
migration at the BBB in MS. The experimental design of Project 2 will define how DBSI
determined cellularity and edema changes responding to various degrees of BBB abnormality
and cell infiltration in EAE mice.
项目2将确定如何靶向分子,调节渗透性和极性,
中枢神经系统(CNS)内皮屏障影响神经炎症,通过
多发性硬化症(MS)小鼠模型的新型神经成像模式。我们已经表明
MS病变中的内皮细胞表现出极性改变,显示出近腔趋化因子
CXCL 12沿管腔表面异常沿着。腔外CXCL 12通常用于限制
白细胞进入,而CXCL 12的腔表达与激活增加相关
其信号受体CXCR 4在浸润性白细胞上的表达。我们发现,
CXCL 12受体,CXCR 7(也由CNS内皮表达),是一种重要的调节因子,
白细胞通过CXCL 12从近腔表面内化进入。在初步研究中,
我们还发现,通过S1 P2的1-磷酸鞘氨醇(S1 P)信号传导干扰了近腔神经元的活动,
CXCL 12的表达,然后破坏免疫豁免。因此,具有靶向缺失的小鼠
或给予特异性拮抗剂JTE-013,显示白细胞迁移减少
进入中枢神经系统实质我们假设,细胞膜极性的改变,
CNS内皮屏障处的CXCL 12促进白细胞捕获和迁移到CNS中,
有助于建立复发缓解型CNS疾病周期
自身免疫我们已经确定了几种调节这一过程的分子,
逆转定位信号CXCL 12的顶基表达。在本提案中,我们将
检查CXCR 7和S1 P2在中枢神经系统淋巴细胞运输和炎症中的作用
使用包括双光子活体内的新型成像方式的自身免疫性疾病
显微镜和纵向使用扩散基光谱成像(DBSI),
区分和量化活小鼠的细胞结构和水肿(参见项目1),
尸检的人MS患者和对照CNS组织的检查。
我们预计DBSI比Gd增强对炎症更敏感,包括在
设置不太深刻的血脑屏障改变。来确定
内皮细胞和免疫细胞(Th 1对Th 17)的相互作用和BBB完整性的丧失,我们将
直接比较使用活体成像与DBSI和Gd增强的结果,
动物为了阐明内皮细胞极性和定位信号的机制,
通过与炎症细胞的相互作用诱导,我们将利用体外和原位方法,
人体组织因此,目标1将确定CXCR 7介导的CXCL 12的内化是否
在EAE期间需要Th 1相对于Th 17细胞的浸润。目标2将确定S1 P2-
介导的内皮细胞极性逆转导致T细胞捕获和进入增加,
EAE和Aim 3将检测CXCR 7和S1 PR 2活化与T细胞增殖的关系。
在MS的BBB迁移。项目2的实验设计将定义DBSI如何
确定的细胞结构和水肿变化响应于不同程度的BBB异常
和细胞浸润。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robyn S Klein其他文献
West Nile virus: crossing the blood-brain barrier
西尼罗河病毒:穿越血脑屏障
- DOI:
10.1038/nm1204-1294 - 发表时间:
2004-12-01 - 期刊:
- 影响因子:50.000
- 作者:
Michael S Diamond;Robyn S Klein - 通讯作者:
Robyn S Klein
Infectious diseases research in 2024: insights into dementia
2024 年传染病研究:对痴呆症的见解
- DOI:
10.1016/s1474-4422(24)00497-6 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:45.500
- 作者:
Robyn S Klein - 通讯作者:
Robyn S Klein
Robyn S Klein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robyn S Klein', 18)}}的其他基金
2023 Neuroimmune Communication in Health and Disease Gordon Research Conference and Gordon Research Seminar
2023健康与疾病中的神经免疫通讯戈登研究会议暨戈登研究研讨会
- 批准号:
10609280 - 财政年份:2022
- 资助金额:
$ 28.31万 - 项目类别:
Research Program Award (R35 Clinical Trial Optional) - Dr. Robyn Klein NINDS
研究计划奖(R35 临床试验可选)- Robyn Klein NINDS 博士
- 批准号:
10397683 - 财政年份:2021
- 资助金额:
$ 28.31万 - 项目类别:
Research Program Award (R35 Clinical Trial Optional) - Dr. Robyn Klein NINDS
研究计划奖(R35 临床试验可选)- Robyn Klein NINDS 博士
- 批准号:
10239672 - 财政年份:2021
- 资助金额:
$ 28.31万 - 项目类别:
Astrocyte innate immune mechanisms of post-viral cognitive dysfunction
病毒后认知功能障碍的星形胶质细胞先天免疫机制
- 批准号:
10115451 - 财政年份:2020
- 资助金额:
$ 28.31万 - 项目类别:
Innate immune mechanisms of virologic control and recovery from flavivirus encephalitis
黄病毒脑炎病毒学控制和恢复的先天免疫机制
- 批准号:
10247164 - 财政年份:2020
- 资助金额:
$ 28.31万 - 项目类别:
Mechanisms of sex differences in blood-brain barrier biology
血脑屏障生物学中性别差异的机制
- 批准号:
9090530 - 财政年份:2016
- 资助金额:
$ 28.31万 - 项目类别:
Mechanisms of sex differences in blood-brain barrier biology
血脑屏障生物学中性别差异的机制
- 批准号:
9204440 - 财政年份:2016
- 资助金额:
$ 28.31万 - 项目类别:
Targeting the BBB to treat CNS inflammation
靶向 BBB 治疗中枢神经系统炎症
- 批准号:
8826187 - 财政年份:2008
- 资助金额:
$ 28.31万 - 项目类别:
Targeting the BBB to treat CNS inflammation
靶向 BBB 治疗中枢神经系统炎症
- 批准号:
8741885 - 财政年份:2008
- 资助金额:
$ 28.31万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 28.31万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 28.31万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 28.31万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 28.31万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 28.31万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 28.31万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 28.31万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 28.31万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 28.31万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 28.31万 - 项目类别:
Research Grant